2013-02-20 |
1 |
|
. 7,932,241 (“the ‘241 patent”) directed to certain approved presentations for
zoledronic acid.
5. Upon…Novartis’ patent rights can be
enforced
4. The three patents awarded to Novartis by the U.S. Patent and Trademark…are:
U.S. Patent No. 8,324,189 (“the ‘189 patent”) directed to oncology methods, U.S. Patent No.
8,052,987…ACTION
2. This is an action for patent infringement under the patent laws of the United States,
Title…987 patent”) directed to methods for treating abnormally increased bone turnover,
and U.S. Patent No. |
External link to document |
2013-03-27 |
146 |
Exhibit 2 |
one Pozen patent (U.S. Patent 6,926,907—“the ‘907 patent”) and five
AstraZeneca patents (not at issue… responses with regard to the ‘907 patent only. The
‘907 patent has 55 claims. On November 17, 2011…907 patent. Subsequently, Plaintiffs
further narrowed their asserted claims of the ‘907 patent to …VIMOVO® drug prior to the expiration of Plaintiffs’ patents. Id.
DRL is the first ANDA filer for…dkt. nos. 41 and 82.
A. The ‘907 Patent
Plaintiffs seek leave to amend their |
External link to document |
2013-04-30 |
225 |
|
primarily on the assertion of U.S. Patent No. 7,932,241 (“the ’241 patent”) in both the
2012 Case and …U.S. Patent No. 8,052,987 (“the ’987 patent”)
and U.S. Patent No. 8,324,189 (“the ’189 patent”), which…and the February 2013 Case. The ’241 patent is the only patent from which Novartis
asserted claims in…which are method of use patents asserted in
the 2013 Cases, the ’241 patent is directed to the packaging…to improperly skirt the Local Patent Rules and revive the ’987
patent in the 2012 Case. Wockhardt is |
External link to document |
2013-05-13 |
236 |
|
respect to U.S. Patent Nos. 7,932,241 and 8,052,987.
Hospira alleged that these patents are invalid, …must include, among other things, the patent number of any patent that
claims the drug or a method of… THE ’241 PATENT
14. The ’241 patent was issued on April 26, 2011, to…of using” zoledronic acid and is a patent for which a claim of patent infringement
could reasonably … THE ’987 PATENT
20. The ’987 patent was issued on November 8, 2011, |
External link to document |
2013-05-13 |
237 |
|
Novartis sued Wockhardt on U.S. Patent No. 8,052,987 (“the ’987 patent”)
in Count II of the 2012 Case…fact that
Novartis now has patent disputes regarding the ’987 patent with additional
defendants …avoid this Court’s Local
Patent Rules by re-asserting the ’987 patent in a new case. Perhaps because… claims of the ’987 patent, thereby waiving
its ability to assert that patent against Wockhardt in… Novartis was aware that U.S. Patent No. 8,324,189
(“the ’189 patent”) had been allowed, and Novartis |
External link to document |
2013-05-14 |
239 |
REDACTED - Novartis Opposition to Wockhardts Motion to Dismiss |
infringement of U.S. Patent No. 8,052,987 (the “’987 patent”).
That patent covers methods of treating…under the Local Patent Rules, to add claims from the ‘987 patent. Even though
that patent has always been…infringement of the ‘987 patent.
Novartis has thus sued these defendants under the U.S. patent laws, 35 U.S.C… Novartis’s patent rights. So Wockhardt
instead took the position that the ‘987 patent is invalid …financial losses.
The ‘987 patent is one of the three patents at issue in this case. But the theory |
External link to document |